The branched‐chain α‐ketoacid dehydrogenase ( BCKDH ) complex regulates branched‐chain amino acid ( BCAA ) catabolism by controlling the second step of this catabolic pathway. In the present study, we examined the in vivo effects of treatment with an mTORC 1 inhibitor, rapamycin, on cardiac BCKDH complex activity in mice. Oral administration of leucine in control mice significantly activated the cardiac BCKDH complex with an increase in cardiac concentrations of leucine and α‐ketoisocaproate. However, rapamycin treatment significantly suppressed the leucine‐induced activation of the complex despite similar increases in cardiac leucine and α‐ketoisocaproate levels. Rapamycin treatment fully inhibited mTORC 1 activity, measured by the phosphorylation state of ribosomal protein S6 kinase 1. These results suggest that mTORC 1 is involved in the regulation of cardiac BCAA catabolism.
Plasma concentrations of amino acids reflect the intracellular amino acid pool in mammals. However, the regulatory mechanism requires clarification. In this study, we examined the effect of leucine administration on plasma amino acid profiles in mice with and without the treatment of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) or rapamycin as an inhibitor of system L or mammalian target of rapamycin complex 1, respectively. The elevation of plasma leucine concentration after leucine administration was associated with a significant decrease in the plasma concentrations of isoleucine, valine, methionine, phenylalanine, and tyrosine; BCH treatment almost completely blocked the leucine-induced decrease in plasma amino acid concentrations. Rapamycin treatment had much less effects on the actions of leucine than BCH treatment. These results suggest that leucine regulates the plasma concentrations of branched-chain amino acids, methionine, phenylalanine, and tyrosine, and that system L amino acid transporters are involved in the leucine action.
Branched-chain amino acids (BCAAs: leucine, isoleucine, and valine) are nutritionally indispensable (essential) amino acids for humans. We acquire these amino acids mainly as food proteins, in which the BCAAs account for ~20% of the amino acids. The ingested BCAAs are used for protein synthesis in the body. The daily requirement for BCAAs in adults is estimated to be 85 mg/kg body weight (BW) (39, 20, and 26 mg/ kg BW for Leu, Ile, and Val, respectively) using methods such as indicator amino acid oxidation and 24-hour balance studies (1). The primary physiological function of BCAAs is as the building blocks of proteins; however, recent studies have contributed to the mounting evidence for other physiological functions. In this review, we summarize the current findings on the physiological functions of BCAAs, including those from our own studies. Regulation of BCAA CatabolismThe main BCAA catabolic pathway occurs within mitochondria. The first 2 steps of the pathway are common to the 3 BCAAs and are especially important for the regulation of BCAA catabolism (2) (Fig. 1). The first step of the pathway is the reversible transamination of BCAAs catalyzed by branched-chain aminotransferase (BCAT) to produce corresponding branched-chain a-ketoacids (BCKAs). The second step involves the oxidative decarboxylation of BCKAs catalyzed by the BCKA dehydrogenase (BCKDH) complex to produce corresponding CoA esters. Since this reaction is irreversible, it is a rate-limiting step in BCAA catabolism. Furthermore, the BCKDH complex is subject to covalent modification; BCKDH kinase (BDK) is responsible for inactivation of the complex by phosphorylation and BCKDH phosphatase reactivates the complex by dephosphorylation (2). Therefore, the enzyme activity of the BCKDH complex can be quickly changed in response to alterations in physiological conditions. Aberrations of the enzymes involved in the first two steps of BCAA catabolism have a great impact on the circulating concentrations of BCAAs; a defect in the mitochondrial BCAT (BCAT2) gene of mice resulted in a markedly high level of plasma BCAAs (3), and BDK-knockout (KO) mice, in which the BCKDH complex in all tissues was almost fully activated, showed significantly low concentrations of plasma BCAAs (4). Regulation of Protein Metabolism by LeucineThe mammalian target of rapamycin complex 1 (mTORC1) is a serine-threonine protein kinase that controls translation initiation and is responsive to cellular levels of free amino acids (5). mTORC1 phosphorylates and activates the protein kinase p70S6K1, which subsequently phosphorylates eukaryotic initiation factor 4B (eIF4B) and programmed cell death 4 (PDCD4), and phosphorylates eIF4E-binding protein 1 (eIF4E-BP1), thereby permitting eIF4E to associate with eIF4G to form eIF4F. Thus, mTORC1 stimulates the joining of mRNA to the 43S preinitiation complex and has a global effect on protein synthesis. Furthermore, mTORC1 regulates cellular proteolysis by inhibiting the formation of autophagosomes (6). It is also known that leucine strongly...
Polysaccharides extracted from Agrocybe aegerita (AAPS) have various physiological effects. In this study, we used the naturally aging Drosophila melanogaster and D-galactose-induced aging mice as animal models to study the anti-aging effects of AAPS via the alleviation of oxidative stress and regulation of gut microbiota. Results showed that AAPS could significantly prolong lifespan and alleviate oxidative stress induced by H2O2 of Drosophila melanogaster. In addition, AAPS significantly increased the activities of antioxidant enzymes in Drosophila melanogaster and mice, and reduced the content of MDA. Furthermore, AAPS reshaped the disordered intestinal flora, increased the abundance ratio of Firmicutes to Bacteroidetes, and increased the abundance of beneficial bacteria Lactobacillus. Our results demonstrated that AAPS had good antioxidant and potential anti-aging effects in vivo.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.